Mwangi John, Litteken Chase, Gorthi Ramya, Attoti Yeswanth, Atluri Rama
Pulmonary and Critical Care Medicine, Saint Louis University School of Medicine, Saint Louis, USA.
Internal Medicine, Saint Louis University School of Medicine, Saint Louis, USA.
Cureus. 2021 Nov 2;13(11):e19218. doi: 10.7759/cureus.19218. eCollection 2021 Nov.
Interstitial lung disease or ILD can be described as inflammation, fibrosis, or scarring of the lung's interstitial, resulting in dyspnea. ILD represents a group of heterogeneous parenchymal lung disorders with complex pathophysiology, differentiated by the clinical and radiological patterns. ILD is one of the most serious pulmonary complications associated with connective tissue diseases (CTDs), resulting in significant morbidity and mortality. Nonspecific interstitial pneumonia is the most common morphological and pathological pattern of ILD seen in CTDs. There are limitations in the therapeutic options resulting in significant morbidity. Certain biologic therapies are being evaluated for the various forms of ILD. The ILD, in this case, is associated with systemic lupus erythematosus (SLE) and scleroderma overlap that was effectively treated with belimumab, a recombinant monoclonal antibody against the B-cell activating factor (B-lymphocyte stimulator).
间质性肺疾病（ILD）可描述为肺部间质的炎症、纤维化或瘢痕形成，导致呼吸困难。ILD代表一组具有复杂病理生理学的异质性实质性肺部疾病，通过临床和放射学模式进行区分。ILD是与结缔组织病（CTD）相关的最严重肺部并发症之一，会导致显著的发病率和死亡率。非特异性间质性肺炎是CTD中ILD最常见的形态学和病理学模式。治疗选择存在局限性，导致发病率较高。目前正在评估某些生物疗法对各种形式ILD的疗效。在这种情况下，ILD与系统性红斑狼疮（SLE）和硬皮病重叠相关，使用贝利尤单抗（一种针对B细胞活化因子（B淋巴细胞刺激因子）的重组单克隆抗体）进行有效治疗。
